Literature DB >> 29036330

Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.

Steffen Ventz1, Matteo Cellamare2, Giovanni Parmigiani3, Lorenzo Trippa3.   

Abstract

Multi-arm clinical trials use a single control arm to evaluate multiple experimental treatments. In most cases this feature makes multi-arm studies considerably more efficient than two-arm studies. A bottleneck for implementation of a multi-arm trial is the requirement that all experimental treatments have to be available at the enrollment of the first patient. New drugs are rarely at the same stage of development. These limitations motivate our study of statistical methods for adding new experimental arms after a clinical trial has started enrolling patients. We consider both balanced and outcome-adaptive randomization methods for experimental designs that allow investigators to add new arms, discuss their application in a tuberculosis trial, and evaluate the proposed designs using a set of realistic simulation scenarios. Our comparisons include two-arm studies, multi-arm studies, and the proposed class of designs in which new experimental arms are added to the trial at different time points.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29036330      PMCID: PMC5862294          DOI: 10.1093/biostatistics/kxx030

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  18 in total

1.  Bootstrap methods for adaptive designs.

Authors:  W F Rosenberger; F Hu
Journal:  Stat Med       Date:  1999-07-30       Impact factor: 2.373

2.  I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Authors:  A D Barker; C C Sigman; G J Kelloff; N M Hylton; D A Berry; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2009-05-13       Impact factor: 6.875

Review 3.  Multi-arm clinical trials of new agents: some design considerations.

Authors:  Boris Freidlin; Edward L Korn; Robert Gray; Alison Martin
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

4.  Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.

Authors:  Robert K Hills; Alan K Burnett
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

5.  The platform trial: an efficient strategy for evaluating multiple treatments.

Authors:  Scott M Berry; Jason T Connor; Roger J Lewis
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

6.  Bayesian response-adaptive designs for basket trials.

Authors:  Steffen Ventz; William T Barry; Giovanni Parmigiani; Lorenzo Trippa
Journal:  Biometrics       Date:  2017-02-17       Impact factor: 2.571

7.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

Review 8.  Practical Bayesian adaptive randomisation in clinical trials.

Authors:  Peter F Thall; J Kyle Wathen
Journal:  Eur J Cancer       Date:  2007-02-16       Impact factor: 9.162

Review 9.  Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

Authors:  James M S Wason; Lynne Stecher; Adrian P Mander
Journal:  Trials       Date:  2014-09-17       Impact factor: 2.279

10.  A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.

Authors:  James M S Wason; Lorenzo Trippa
Journal:  Stat Med       Date:  2014-01-14       Impact factor: 2.373

View more
  6 in total

1.  To add or not to add a new treatment arm to a multiarm study: A decision-theoretic framework.

Authors:  Kim May Lee; James Wason; Nigel Stallard
Journal:  Stat Med       Date:  2019-05-21       Impact factor: 2.373

2.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  Inference in response-adaptive clinical trials when the enrolled population varies over time.

Authors:  Massimiliano Russo; Steffen Ventz; Victoria Wang; Lorenzo Trippa
Journal:  Biometrics       Date:  2021-10-21       Impact factor: 1.701

4.  Including non-concurrent control patients in the analysis of platform trials: is it worth it?

Authors:  Kim May Lee; James Wason
Journal:  BMC Med Res Methodol       Date:  2020-06-24       Impact factor: 4.615

5.  The effects of releasing early results from ongoing clinical trials.

Authors:  Steffen Ventz; Sergio Bacallado; Rifaquat Rahman; Sara Tolaney; Jonathan D Schoenfeld; Brian M Alexander; Lorenzo Trippa
Journal:  Nat Commun       Date:  2021-02-05       Impact factor: 14.919

6.  Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats.

Authors:  Kim May Lee; Louise C Brown; Thomas Jaki; Nigel Stallard; James Wason
Journal:  Trials       Date:  2021-03-10       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.